Amgen and AstraZeneca partner on 5 biotech drugs

04/2/2012 | Reuters

AstraZeneca and Amgen agreed to jointly develop and market five Amgen biotech drug candidates for the treatment of autoimmune, respiratory and inflammatory diseases. Amgen will receive $50 million upfront, and the partners will share development costs and profit. The deal covers brodalumab for psoriasis, psoriatic arthritis and asthma; AMG 557 for lupus; AMG 139 for Crohn's disease; AMG 157 for asthma; and AMG 181 for ulcerative colitis and Crohn's.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY